Literature DB >> 7764815

The tularaemia vaccine.

G Sandström1.   

Abstract

Tularaemia is a disease caused by the facultative intracellular bacterium Francisella tularensis. Vaccination resulting in protective immunity is induced by live vaccine only. Such vaccination can be performed by scarification utilizing the live vaccine strain of F. tularensis (F. tularensis LVS), which results in good but not complete protection. Humoral as well as cell-mediated immunity are induced by vaccination and it has been shown that cell-mediated immunity is a prerequisite for protection. Since the live vaccine strain is attenuated and the genetic background of attenuation is unknown it is important to consider process parameters so that the immunogenicity of the vaccine is preserved.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7764815     DOI： 10.1002/jctb.280590402

Source DB:  PubMed          Journal:  J Chem Technol Biotechnol        ISSN： 0268-2575            Impact factor:   3.174


  25 in total

1.  Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity.

Authors:  C M Bosio; K L Elkins
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling.

Authors:  Leah E Cole; Michelle H W Laird; Anna Seekatz; Araceli Santiago; Zhaozhao Jiang; Eileen Barry; Kari Ann Shirey; Katherine A Fitzgerald; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

3.  Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR.

Authors:  R Grunow; W Splettstoesser; S McDonald; C Otterbein; T O'Brien; C Morgan; J Aldrich; E Hofer; E J Finke; H Meyer
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.

Authors:  Sherry L Kurtz; Oded Foreman; Catharine M Bosio; Miriam R Anver; Karen L Elkins
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

5.  Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Authors:  Tae-Hyun Kim; Jessica T Pinkham; Sara J Heninger; Sabina Chalabaev; Dennis L Kasper
Journal:  J Infect Dis       Date:  2011-10-03       Impact factor: 5.226

6.  Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins.

Authors:  P Ancuta; T Pedron; R Girard; G Sandström; R Chaby
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

7.  Novel modification of lipid A of Francisella tularensis.

Authors:  Nancy J Phillips; Birgit Schilling; Molly K McLendon; Michael A Apicella; Bradford W Gibson
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Survival and growth of Francisella tularensis in Acanthamoeba castellanii.

Authors:  Hadi Abd; Thorsten Johansson; Igor Golovliov; Gunnar Sandström; Mats Forsman
Journal:  Appl Environ Microbiol       Date:  2003-01       Impact factor: 4.792

9.  Cytokine expression in the liver during the early phase of murine tularemia.

Authors:  I Golovliov; G Sandström; M Ericsson; A Sjöstedt; A Tärnvik
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

Review 10.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.